Format

Send to

Choose Destination
Stem Cell Reports. 2017 Jul 11;9(1):355-365. doi: 10.1016/j.stemcr.2017.05.010. Epub 2017 Jun 8.

CryoPause: A New Method to Immediately Initiate Experiments after Cryopreservation of Pluripotent Stem Cells.

Author information

1
The SKI Stem Cell Research Facility, The Center for Stem Cell Biology and Developmental Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
2
The Antitumor Assessment Core Facility, Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
3
Zentrum für Integrative Psychiatrie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Niemannsweg 147, 24105 Kiel, Germany.
4
Division of Hematology and Medical Oncology, Department of Medicine and Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY 10065, USA.
5
The SKI Stem Cell Research Facility, The Center for Stem Cell Biology and Developmental Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA. Electronic address: tomishim@mskcc.org.

Abstract

Human pluripotent stem cells (PSCs) provide an unlimited cell source for cell therapies and disease modeling. Despite their enormous power, technical aspects have hampered reproducibility. Here, we describe a modification of PSC workflows that eliminates a major variable for nearly all PSC experiments: the quality and quantity of the PSC starting material. Most labs continually passage PSCs and use small quantities after expansion, but the "just-in-time" nature of these experiments means that quality control rarely happens before use. Lack of quality control could compromise PSC quality, sterility, and genetic integrity, which creates a variable that might affect results. This method, called CryoPause, banks PSCs as single-use, cryopreserved vials that can be thawed and immediately used in experiments. Each CryoPause bank provides a consistent source of PSCs that can be pre-validated before use to reduce the possibility that high levels of spontaneous differentiation, contamination, or genetic integrity will compromise an experiment.

KEYWORDS:

cell banking; cell therapy; cryopreservation; directed differentiation; disease modeling; human pluripotent stem cell; quality control

PMID:
28602613
PMCID:
PMC5511100
DOI:
10.1016/j.stemcr.2017.05.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center